FOSFOMYCIN DISTRIBUTION IN THE LOWER URINARY-TRACT AFTER ADMINISTRATION OF FOSFOMYCIN TROMETAMOL SALT

Fosfomycin trometamol (FT) is a new fosfomycin salt with pharmacokinet ic characteristics allowing hypothesis of its use in the single-dose t herapy of lower urinary tract infections. in this study the diffusion of fosfomycin into bladder mucosa and urine after administration of a single oral dose of FT (3 g) was evaluated in patients affected by bla dder or prostatic carcinoma having to undergo surgery. The administrat ion of FT was scheduled in order to obtain blood, urine and tissue sam ples, to be collected during surgical operation at different times pos t administration. The peak concentrations in serum and bladder mucosa were detected within 3 h and 6 h respectively. Fosfomycin concentratio ns in bladder mucosa proved to be higher than the MICs of the most com mon urinary tract pathogens for at least 36 h. In urine, fosfomycin re ached concentrations markedly higher than those found in serum and bla dder mucosa, antibacterial levels lasting until the 48th hour post dos ing. Fosfomycin trometamol, because of its pharmacokinetic and pharmac odynamic properties, appears to be suitable for single-dose therapy of uncomplicated UTIs.